Clinical trials: Essential Hypertension.
Hypertension
An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure
To assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg / amlodipine 10 mg in patients with essential hypertension (Mean Sitting Diastolic Blood Pressure [msDBP] ≥ 90 mmHg and < 110 mmHg).
- Trial name
- NCT00402103
- Testing
- Aliskiren, Amlodipine, Hydrochlorothiazide
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 556 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with chlorthalidone in treating individuals with essential hypertension, compared to treatment with…
- Trial name
- NCT00591773
- Testing
- Azilsartan medoxomil and chlorthalidone, Chlorthalidone
- Where
- 46 sites in United States
- Volunteers
- 551 people
- Sponsor
- Takeda
Essential Hypertension Complicated by Type 2 Diabetes Mellitus
A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R
Multicenter, randomized, open-label, parallel-group exploratory study to explore the effects of azilsartan (Azirva), compared with telmisartan, on insulin resistance in participants with essential hypertension complicated by type…
- Trial name
- NCT02079805
- Testing
- Azilsartan, Telmisartan
- Where
- Japan
- Volunteers
- 33 people
- Sponsor
- Takeda
Hypertension
Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension
The primary objective of this study was to assess the anti-hypertensive effect of OM/HCTZ 40/12.5 mg combination therapy compared to OM 40 mg monotherapy in lowering sitting diastolic BP in hypertensive patients after 8 weeks of…
- Trial name
- NCT00441350
- Testing
- OM 40, OM/HCTZ 40/12.5
- Where
- 65 sites in Croatia, Czechia and 6 more
- Volunteers
- 1,004 people
- Sponsor
- Menarini Group
Hypertension, Systolic, Cerebrovascular Disease
Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People
This randomized clinical trial examines if lowering and maintaining 24-hour ambulatory systolic blood pressure to <130 mmHg (intensive control) versus <145 mmHg (standard control) slows/halts the progression of deterioration of…
- Trial name
- NCT01650402
- Testing
- Anti-hypertensive therapy to SBP 130 mm Hg, Anti-hypertensive therapy to SBP 145 mm Hg
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- UConn Health
Hypertension
Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg
Assess that for an equivalent brachial blood pressure (BP)lowering, a fixed dose combination amlodipine/valsartan based regimen reduces central aortic BP pressure to a larger extent than an atenolol/amlodipine combination based…
- Trial name
- EXPLOR (NCT00687973)
- Testing
- Valsartan/amlodipine 80/5 mg tablets, Amlodipine 5 mg capsules, Amlodipine 10 mg capsules
- Where
- France
- Volunteers
- 393 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study
This is a multi-center, randomized, double-blind, 6 x 3 cross-over study. All patients who meet the entry criteria will be required to stop taking any other anti-hypertensive agents than Adalat CR (controlled release), if taken…
- Trial name
- NCT00768560
- Testing
- Nifedipine (Adalat CR, BAYA1040) 80mg OD, Nifedipine (Adalat CR, BAYA1040) 40mg BID, Nifedipine (Adalat CR, BAYA1040) 40mg OD
- Where
- 3 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Bayer
Essential Hypertension
Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
The purpose of the study was to evaluate the efficacy (blood pressure lowering effect) and safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in patients with essential hypertension (mean sitting diastolic…
- Trial name
- NCT01237223
- Testing
- Aliskiren/Amlodipine 150/2.5 mg, Aliskiren/amlodipine 150/5 mg, Aliskiren 150 mg
- Where
- 11 sites in Japan
- Volunteers
- 1,342 people
- Sponsor
- Novartis
Hypertension
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension.
- Trial name
- NCT00739973
- Testing
- Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 2,694 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
This study was a proof-of-efficacy, dose finding study of LCI699 in participants with mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure (BP) lowering effect, safety and tolerability of…
- Trial name
- NCT00758524
- Testing
- LCI699, Eplerenone
- Where
- United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan)
Evaluated the incidence and characteristics of adverse events during the treatment for Kanarb tablet.
- Trial name
- NCT02385721
- Where
- South Korea
- Volunteers
- 601 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine
This study will assess whether LCZ696 when used in combination with amlodipine will provide greater BP lowering benefit compared to amlodipine alone in Asian hypertensive patients not adequately responsive to amlodipine therapy.
- Trial name
- NCT01663233
- Testing
- LCZ696, Amlodipine
- Where
- 28 sites in China, Japan and 4 more
- Volunteers
- 266 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension
Both Olmesartan (OLM)/Amlodipine (AML) combination and Hydrochlorothiazide (HCTZ) have proven to be efficacious and safe in lowering blood pressure, but may not always be sufficient.
- Trial name
- NCT00902538
- Testing
- Olmesartan medoxomil 40 mg - Amlodipine 10 mg, Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg, Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg
- Where
- 117 sites in Austria, Belgium and 12 more
- Volunteers
- 2,204 people
- Sponsor
- Daiichi Sankyo
Essential Hypertension
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension.
- Trial name
- NCT02603809
- Testing
- Aprocitentan 5 mg, Aprocitentan 10 mg, Aprocitentan 25 mg
- Where
- 90 sites in United States, Canada and 2 more
- Volunteers
- 1,659 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Systolic Hypertension
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
The purpose of the study is to evaluate dose response of blood pressure lowering for 4 doses of AHU377, given once daily (50 mg, 100 mg, 200 mg and 400 mg) in combination with a fixed dose of valsartan (320 mg).
- Trial name
- NCT01281306
- Testing
- LCZ696, Valsartan, AHU377
- Where
- 90 sites in United States, Argentina and 7 more
- Volunteers
- 910 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient
The changes in the trough systolic blood pressure from the baseline were assessed after 8 weeks of double-blind treatment with amlodipine 10 mg or amlodipine 5 mg
- Trial name
- NCT00415623
- Testing
- Amlodipine
- Where
- 14 sites in Japan
- Volunteers
- 305 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension
Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension
The purpose of this study is to evaluate the effectiveness and safety of azilsartan medoxomil compared to placebo, once daily (QD), in African-American participants with essential hypertension.
- Trial name
- NCT00591253
- Testing
- Azilsartan medoxomil
- Where
- 64 sites in United States, Puerto Rico
- Volunteers
- 413 people
- Sponsor
- Takeda
Essential Hypertension, Type 2 Diabetes Mellitus
Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil (AZM) in Asian adult participants with both essential hypertension and type 2 diabetes.
- Trial name
- NCT02517866
- Testing
- Azilsartan Medoxomil
- Where
- 11 sites in China, Taiwan and 1 more
- Volunteers
- 380 people
- Sponsor
- Takeda
Hypertension
Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension
This study is a phase 2 study in patients with essential hypertension.
- Trial name
- NCT01193101
- Testing
- LCZ696
- Where
- 34 sites in China, Japan and 3 more
- Volunteers
- 389 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension
This was the first evaluation of the effects of LCZ696 on local and regional measures of aortic stiffness in subjects with mild to moderate hypertension and widened pulse pressure.
- Trial name
- NCT01870739
- Testing
- sacubitril/valsartan (LCZ696), olmesartan, Amlodipine (Optional)
- Where
- 4 sites in Germany, Switzerland and 1 more
- Volunteers
- 115 people
- Sponsor
- Novartis Pharmaceuticals